Non-alcoholic Steatohepatitis Biomarkers Market, By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others), By End-user (Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes), and By Region- Trends, Analysis, and Forecast till 2029

Report Code: PMI441320 | Publish Date: March 2024 | No. of Pages: 160

Global Non Alcoholic Steatohepatitis Biomarkers Market Overview

Non-alcoholic Steatohepatitis Biomarkers Market accounted for USD 1433.1 Million in 2024 and is estimated to be USD 10976.2 Million by 2034 and is anticipated to register a CAGR of 25.10%

Non-alcoholic steatohepatitis is a progressive phase of non-alcoholic fatty liver disease (NAFLD), which is caused due to the excess fat accumulation leading to inflammation and damage resulting to liver scarring. NASH biomarkers are used as diagnostic tools to measure the severity of non-alcoholic steatohepatitis and for the liver damage assessment. Emerging advancements in technology in biomarker identification for NASH is supporting in the NASH biomarker development.

Global Non Alcoholic Steatohepatitis Biomarkers Market Drivers & Restraints

Increase in Prevalence of NAFLD and NASH

The prevalence rate of non-alcoholic liver diseases has grown significantly. Patients with obesity and type 2 diabetes are projected to be more susceptible to NAFLD and other liver diseases. This is projected to drive the prevalence of non-alcoholic liver diseases. High pollution levels and changes in lifestyle are expected to propel the prevalence of nonalcoholic liver diseases. This, in turn, is anticipated to propel the NASH biomarkers market over the forecast period.

Growth in the number of initiatives concerning to development of NASH drugs

The biopharmaceutical company named “GENFIT” has undertaken an initiative for NASH Education Program in 2016. It’s a public health initiative aimed to create awareness about NASH among patients. These types of programs are measured to expedite utilization of NASH therapeutics. Moreover, GENFIT started Pediatric NAFLD/NASH Program in Europe after approval of elafibranor’s Pediatric Investigation Plan by the European Medicine Agency, which is further expected to ease the drug development program in the future.

Conversely, higher cost of treatment is anticipated to limit the growth of the non-alcoholic steatohepatitis biomarkers market during the forecast period.

Global Non Alcoholic Steatohepatitis Biomarkers Market Segmentations & Regional Insights

The non-alcoholic steatohepatitis biomarkers market is segmented based on the type, end-user, and region.

On the basis of the type, the non-alcoholic steatohepatitis biomarkers market is segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. Based on the end-user, the target market is classified into pharma & CRO industry, hospitals, diagnostic labs, and academic research institutes.

Regional Insights:

In the region, the non-alcoholic steatohepatitis biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account the dominating position in the non-alcoholic steatohepatitis (NASH) biomarkers market in the upcoming years. Driving government initiatives, the presence of sophisticated healthcare amenities, and the growing incidence of diabetes, obesity, and fatty liver disease is supporting the growth of the target market in this region. Europe is anticipated to account the second position in the non-alcoholic steatohepatitis (NASH) biomarkers market, owing to the growing prevalence of NASH, increasing incidence of obesity and diabetics, growing research and development on liver diseases, and the existence of well-established healthcare sector. The market in the Asia-Pacific region is boosting the growth due to the existence of a large patient base, availability of skilled healthcare personnel, and growth in healthcare spending. The Middle East and Africa is projected to witness the lowest share in the market. In the African region, the market is projected to be negatively affected by factors like poor healthcare amenities, inadequate awareness about liver diseases including NASH, and a smaller amount of disposable income.

Attribute

Details

The base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Million & CAGR from 2024 – 2034

Market Segmentation

By Type - Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others

By End-user – Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2029.  For the purpose of this study, has segmented the non-alcoholic steatohepatitis biomarkers market report based on type, end-user, and region.

Non-alcoholic Steatohepatitis Biomarkers Market, By Type:

  • Serum biomarkers
  • Hepatic fibrosis biomarkers
  • Apoptosis biomarkers
  • Oxidative stress biomarkers
  • Others

Non-alcoholic Steatohepatitis Biomarkers Market, By End-user:

  • Pharma & CRO Industry
  • Hospitals
  • Diagnostic Labs
  • Academic Research Institutes

Non-alcoholic Steatohepatitis Biomarkers Market, By Region:

  • North America
    • Middle East & Africa
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
    • Europe
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
    • U.S.
    • Canada

Global Non Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape & Key Players

The key players operating in the non-alcoholic steatohepatitis biomarkers market include GENFIT, Gilead, AstraZeneca, Novartis AG, GE Healthcare, EUSA Pharma, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Allergan Novo Nordisk A/S, and Pfizer, Inc. The market is perceiving intense competition due to the growing number of liver transplantation. Rising demand for advanced diagnostic tools that help in accurate diagnosis of NASH is the key factor boosting growth. Industry players are involved in novel product development and strategic alliances, such as partnership agreements and research collaborations to aid market penetration.

Global Non Alcoholic Steatohepatitis Biomarkers Market Company Profile

  • GENFIT
  • Gilead
  • AstraZeneca
  • Novartis AG
  • GE Healthcare
  • EUSA Pharma
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Allergan Novo Nordisk A/S
  • Pfizer, Inc.

FAQs

The global non-alcoholic steatohepatitis biomarkers market is segmented based on type, end-user, and region.

An increase in the prevalence of NAFLD and NASH is likely to drive the growth of the global non-alcoholic steatohepatitis biomarkers market over the forecast period.

North America is expected to account for the dominating position in the non-alcoholic steatohepatitis (NASH) biomarkers market in the upcoming years.

Industry players are involved in novel product development and strategic alliances, such as partnership agreements and research collaborations to aid market penetration.• For instance, in November 2019, Novartis announced positive interim results from the final part of its phase IIb FLIGHT-FXR adaptive design study, assessing the safety, tolerability, and efficacy of tropifexor in patients with biopsy-confirmed stage 2-3 fibrotic non-alcoholic steatohepatitis (NASH).